This study is a Phase Ib/ll, open-label, multicenter study designed to evaluate the safety and efficacy of 9MW2821 monotherapy or combined with other anticancer therapy in advanced solid tumors.
Competent to comprehend, sign, and date an independent ethics committee/institutional review board/research ethics board (IEC/IRB/REB) approved informed consent form.
Male or female subjects aged 18 to 75 years (including 18 and 75 years).
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
Histopathological diagnosed of recurrent or locally advanced or metastatic solid tumors.
History of another malignancy within 3 years before the first dose of study drug.
Ongoing clinically significant toxicities related to prior treatment.
Grade ≥ 2 peripheral neuropathy.
Severe or uncontrolled gastrointestinal diseases.